// App-Quantinova.ai

2643 : Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.

Researchers

Presenter

  • Hamzah Abu-Sbeih

Principal Investigators

  • Tenglong Tang

  • David M. Faleck

  • Michael L. Dougan

  • Anna Olsson-Brown

  • Douglas Buckner Johnson

  • Dwight Hall Owen

  • David Engar Warner

  • Alexander B Philipp

  • Nick Powell

  • Ella Daniels

  • Jessica Philpott

  • Alison Margaret Weppler

  • David James Pinato

  • Yinghong Wang

Medical Centers

  • University of Missouri Kansas City, Kansas City, MO

  • Xiangya Hospital Central South University, Changsha, China

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • The Clatterbridge Cancer Centre, Liverpool and Wirral, United Kingdom

  • Vanderbilt University Medical Center, Nashville, TN

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Wake Forest Baptist Health, Winston-Salem, NC

  • Department of Medicine III, University Hospital Grosshadern/LMU, Munich, Germany

  • Chelsea and Westminster Hospital, London, United Kingdom

  • Cleveland Clinic, Cleveland, OH

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

  • China

  • United Kingdom

  • Germany

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Infliximab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved